Compare MWA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWA | ERAS |
|---|---|---|
| Founded | 1857 | 2018 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 2006 | 2021 |
| Metric | MWA | ERAS |
|---|---|---|
| Price | $25.09 | $19.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $30.50 | $14.25 |
| AVG Volume (30 Days) | 1.2M | ★ 5.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 64.86 | 36.23 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $1,429,700,000.00 | N/A |
| Revenue This Year | $4.78 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | $38.28 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $22.74 | $1.33 |
| 52 Week High | $31.00 | $24.28 |
| Indicator | MWA | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 59.23 |
| Support Level | $24.81 | $17.63 |
| Resistance Level | $26.05 | $21.60 |
| Average True Range (ATR) | 0.58 | 1.29 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 35.98 | 41.03 |
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments: Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.